SPI Medical Imaging: The Tightrope Upon Which Lunit Must Walk

Medical Imaging AI developer Lunit has recently received preliminary approval to list publicly in South Korea. The prospect of going public represents a natural next step for the vendor, but it is a step that is also fraught with risk.

The insight is part of Signify Research’s Premium Insight – Medical Imaging subscription service.

To view the full insight on this development hit the Request Access button above for either a complimentary one month trial or to purchase a subscription.

The Signify Research’s Premium Insight – Medical Imaging subscription service provides:

• Approximately 100 actionable and up to the moment Premium Insights per year.
• A subscription to Signify Premium Insights – Medical Imaging provides compelling thought leadership on the most pertinent developments in healthcare technology.
• This service utilises Signify Research’s expansive market data to properly appraise and interpret breaking news stories.
• Major market moves and industry-changing announcements are evaluated as they unfold, and the considered opinions of Signify Research’s expert analysts are shared to provide insight into current developments.
• Key vendors, technologies and conferences are followed, with updates carefully scrutinised to ensure that the most important details are revealed and properly assessed.